<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02097082</url>
  </required_header>
  <id_info>
    <org_study_id>480-SFA2013-001</org_study_id>
    <nct_id>NCT02097082</nct_id>
  </id_info>
  <brief_title>Treatment of SFA Lesions With 480 Biomedical STANZA™ Drug-Eluting Resorbable Scaffold (DRS) System</brief_title>
  <acronym>SPRINT</acronym>
  <official_title>An Evaluation of the 480 Biomedical STANZA™ Drug-Eluting Resorbable Scaffold (DRS) System in the Treatment of de Novo SFA Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>480 Biomedical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lyra Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An evaluation of the safety and performance of the STANZA Drug-eluting Resorbable Scaffold&#xD;
      (DRS) system for the treatment of patients with obstructive superficial femoral artery&#xD;
      disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The STANZA DRS system is comprised of a controlled release paclitaxel-eluting bioresorbable&#xD;
      scaffold and a delivery system used in the treatment of superficial femoral artery disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">March 30, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patency by Ultrasound</measure>
    <time_frame>through 6 months</time_frame>
    <description>Patency measured by duplex ultrasound with ≤50% restenosis (Peak Systolic Velocity Ratio (PSVR ≤ 2.4).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major Adverse Events</measure>
    <time_frame>30 days</time_frame>
    <description>Freedom from all causes of death, emergent endovascular intervention or surgical intervention on the target limb, index limb amputation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Success</measure>
    <time_frame>48 hours</time_frame>
    <description>On a per patient basis, technical success without major adverse event (MAE) within 48 hours after the index procedure or at hospital discharge, whichever is sooner.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Success</measure>
    <time_frame>Procedure</time_frame>
    <description>On a per device basis, the achievement of successful delivery and deployment of the study device at the intended target lesion and successful withdrawal of the delivery catheter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical Success</measure>
    <time_frame>Procedure</time_frame>
    <description>Technical success is defined on a per lesion basis, as the achievement of a final residual stenosis of ≤ 30%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patency by Ultrasound</measure>
    <time_frame>12, 24 months</time_frame>
    <description>Patency measured by duplex ultrasound with ≤50% restenosis (PSVR ≤ 2.4) based on core lab evaluation at 12 and 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patency by Angiography</measure>
    <time_frame>12 months</time_frame>
    <description>≤50% diameter stenosis determined by an angiographic core lab analysis of an angiogram performed at 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Driven Target Lesion Revascularization (TLR)</measure>
    <time_frame>6,12, 24 months</time_frame>
    <description>Clinically Driven TLR is defined as symptomatic patients with:&#xD;
Decrease in Ankle Brachial Index (ABI) &gt; 0.15 and Increase in Rutherford Becker Category ≥ 1 from post procedure assessment and &gt;50% stenosis by angiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical Intervention on the target limb, index limb amputation</measure>
    <time_frame>3,6,12, and 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <condition>Intermittent Claudication</condition>
  <condition>Vascular Diseases</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>STANZA Drug-eluting Resorbable Scaffold</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment of Superficial Femoral Artery (SFA) lesion with resorbable scaffold</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>STANZA Drug-eluting resorbable Scaffold</intervention_name>
    <arm_group_label>STANZA Drug-eluting Resorbable Scaffold</arm_group_label>
    <other_name>Paclitaxel-eluting resorbable scaffold</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Age &gt; 18 years.&#xD;
&#xD;
          2. De novo stenotic lesion(s) in the superficial femoral artery located at least 1 cm&#xD;
             distal to the femoral bifurcation and &gt; 5 cm above the joint space of the knee.&#xD;
&#xD;
          3. Patient has symptomatic intermittent claudication affecting at least the target leg&#xD;
             (Rutherford Class 2-3). Patients should have first received conservative medical&#xD;
             management of their symptoms prior to study inclusion. The symptoms can be bilateral.&#xD;
&#xD;
          4. The study patient has been informed of the nature of the study, agrees to its&#xD;
             provisions and has provided written informed consent as approved by the ethics&#xD;
             committee of the respective clinical site.&#xD;
&#xD;
          5. The study patient agrees to comply with all required post-procedure study&#xD;
             requirements.&#xD;
&#xD;
        Baseline Inclusion Criteria&#xD;
&#xD;
          1. Reference vessel diameter (RVD) 5.0 -6.0 mm measured by an objective measurement such&#xD;
             as online Quantitative Vessel Analysis (QVA).&#xD;
&#xD;
          2. Target lesion length ≤ 90 mm; total occlusion length &lt; 40 mm.&#xD;
&#xD;
          3. Target lesion has a ≥70% diameter stenosis.&#xD;
&#xD;
          4. Angiographic evidence of at least one runoff vessel to the ankle/foot without&#xD;
             hemodynamically significant stenosis (&gt;50% diameter stenosis) that does not require&#xD;
             any treatment within 3 months of the index procedure.&#xD;
&#xD;
          5. Procedural access can be accomplished via contralateral vascular access or if&#xD;
             antegrade access no closure device can be utilized and closure has to occur via manual&#xD;
             pressure.&#xD;
&#xD;
          6. Patent common and external iliac: TASC A &amp; B iliac lesions may be treated at the time&#xD;
             of index procedure (before treatment of the target lesion) if residual stenosis is&#xD;
             ≤30%.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Previous vascular surgery/endovascular treatment of the target lesion.&#xD;
&#xD;
          2. Re-vascularization of target vessel within 30 days of study procedure.&#xD;
&#xD;
          3. Critical limb ischemia defined as Rutherford Becker Category 4-6.&#xD;
&#xD;
          4. Known coagulation disorders or intolerance or allergies to aspirin, clopidogrel or&#xD;
             ticlopidine, heparin, any scaffold components, contrast agents which cannot be&#xD;
             adequately pre-medicated.&#xD;
&#xD;
          5. Life expectancy ≤12 months.&#xD;
&#xD;
          6. Planned procedure that necessitates the discontinuation of antiplatelet medications&#xD;
             used in conjunction with the investigational device within 3 months post-procedure.&#xD;
&#xD;
          7. Inability to walk due to orthopedic or other nonvascular complications.&#xD;
&#xD;
          8. Pregnancy or breast feeding or patient desires to become pregnant.&#xD;
&#xD;
          9. Non-atherosclerotic lesion (e.g. vasculitis).&#xD;
&#xD;
         10. Renal insufficiency (serum creatinine level &gt; 220 µmol/L or &gt; 2.5 mg/dl, or patient is&#xD;
             on dialysis).&#xD;
&#xD;
         11. Patient has medical condition(s) which could affect study assessments or may adversely&#xD;
             affect the safety and/or success of the study treatment.&#xD;
&#xD;
         12. Active systemic infection or lower limb infection of any nature.&#xD;
&#xD;
         13. White Blood Cells (WBC) ≤ 3,000 cells/mm3.&#xD;
&#xD;
         14. Myocardial infarction within 30 days prior to the study procedure.&#xD;
&#xD;
         15. Stroke within 90 days prior to the study procedure.&#xD;
&#xD;
         16. Uncontrolled atrial fibrillation.&#xD;
&#xD;
         17. Currently participating in an investigational drug or another device study. Note:&#xD;
             Trials requiring extended follow-up for products that were investigational, but have&#xD;
             since become commercially available, are not considered investigational trials.&#xD;
&#xD;
         18. Prior use of paclitaxel-eluting products in the target limb less than 6 months prior&#xD;
             to index procedure.&#xD;
&#xD;
         19. Patient has known unstable angina.&#xD;
&#xD;
        Baseline Exclusion Criteria&#xD;
&#xD;
          1. Target lesion treatment with a drug eluting balloon.&#xD;
&#xD;
          2. Target lesion treatment with atherectomy, laser, or cryoplasty (use of a cutting or&#xD;
             scoring balloon is permitted prior to scaffold implantation only).&#xD;
&#xD;
          3. Suspicion for or evidence of subintimal passage of guidewire.&#xD;
&#xD;
          4. Severely calcified lesion(s).&#xD;
&#xD;
          5. Target lesion which, based on two angiographic orthogonal views, exhibit a persistent&#xD;
             balloon deformity during pre-dilatation with a nominally sized balloon.&#xD;
&#xD;
          6. Target vessel (superficial femoral artery) has an angiographically significant (&gt; 50%&#xD;
             diameter stenosis) lesion located distally or proximally to the target lesion.&#xD;
&#xD;
          7. Acute embolic complication following pre-dilatation.&#xD;
&#xD;
          8. Target vessel contains an acute thrombus.&#xD;
&#xD;
          9. Aneurysm in target vessel or co-existing clinically significant aneurysmal disease of&#xD;
             the abdominal aorta, iliac or popliteal arteries.&#xD;
&#xD;
         10. Intervention in the infra-inguinal arteries outside of the target lesion.&#xD;
&#xD;
         11. Planned procedure within 30 days after the index procedure.&#xD;
&#xD;
         12. Positive pregnancy test for females of child bearing potential.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Holden, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Auckland City Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitäts Klinikum Graz</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WGKK - Hanusch-Krankenhaus</name>
      <address>
        <city>Vienna</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular and Interventional Radiology- AKH</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäts-Herzzentrum Freiburg-Bad Krozingen GmbH</name>
      <address>
        <city>Bad Krozingen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RoMed Klinikum Rosenheim</name>
      <address>
        <city>Rosenheim</city>
        <state>Bavaria</state>
        <zip>83022</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig AöR</name>
      <address>
        <city>Leipzig</city>
        <state>Saxony</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>INSELSPITAL, Universitätsspital Bern</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>New Zealand</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>March 24, 2014</study_first_submitted>
  <study_first_submitted_qc>March 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2014</study_first_posted>
  <last_update_submitted>September 3, 2019</last_update_submitted>
  <last_update_submitted_qc>September 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peripheral Arterial Disease</keyword>
  <keyword>Intermittent Claudication</keyword>
  <keyword>Vascular Diseases</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Superficial Femoral Artery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Intermittent Claudication</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

